Our recent review of existing literature on the positive and negative effects of approved and currently studied DMT for MS in the context of various coexisting AID emphasizes the necessity for further research in this area [25], particularly in understanding the impact of AID as prognostic factors for MS outcomes and whether the presence of comorbid AID might influence DMT decision-making processes [6, 10]. Here, AICDA is linked to myeloid sarcoma.